Nephrocare Health Services Ltd (NEPHROPLUS) — shareholding pattern, promoter holding, financials and share price
About Nephrocare Health Services Ltd (NEPHROPLUS)
Nephrocare Health Services Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as NEPHROPLUS and on the BSE under scrip code 544647. Its ISIN is INE428V01029.
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. [1]
Nephrocare Health Services Limited (NephroPlus) operates Asia’s largest dialysis network, providing end‑to‑end dialysis care across formats (standalone clinics, captive hospital units, PPPs, home dialysis, dialysis on wheels) with 521 global clinics across India, Philippines, Uzbekistan, Nepal and KSA and over 36,000 guests served as of 9M FY26.
The company reported strong 9M FY26 results with revenue of ₹733.2 crore, adjusted EBITDA of ₹175.4 crore (23.9% margin) and adjusted PAT of ₹85.9 crore, reflecting a high operating leverage model enabled by scale, disciplined consumables procurement, and rapid international mix shift driving higher RPTs and ROCE expansion.
Listed peers in Healthcare Service Provider: Metropolis Healthcare Ltd, Thyrocare Technologies Ltd, Krsnaa Diagnostics Ltd, Suraksha Diagnostic Ltd, One Global Service Provider Ltd, Health X Platform Ltd.
Valuation & Returns
10 Jul 2026At ₹650.75 a share on 10 Jul 2026, Nephrocare Health Services Ltd (NEPHROPLUS) was valued at a price-to-earnings ratio of 83.7x against an industry P/E of 61.73x and a price-to-book of 11.18x on a book value of ₹58.21 per share as of Mar 2025. Solomo computes return on equity of 13.36% and return on capital employed of 18.9% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Mar 2026.
- P/E
- 83.7x
- Industry P/E
- 61.73x
- P/B
- 11.18x
- EPS (TTM)
- ₹7.77
- Book value / share
- ₹58.21
- ROE
- 13.36%
- ROCE
- 18.9%
- ROA
- 7.83%
- Debt / equity
- 0.44x
- Dividend yield
- 0%
- EBITDA margin
- 24.87%
- 52-week range
- ₹445 – ₹767.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Nephrocare Health Services Ltd (NEPHROPLUS) reported revenue of ₹999 crore, net profit of ₹77 crore and earnings per share of ₹7.66. That compares with revenue of ₹756 crore and net profit of ₹67 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹266 crore and net profit ₹30 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 318 | 437 | 566 | 756 | 999 |
| Net profit (₹ cr) | -21 | -12 | 35 | 67 | 77 |
| EPS (₹) | -106.93 | -58.69 | 169.82 | 321.87 | 7.66 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 19.71% | 33.50% |
| Profit growth | - | 91.00% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.85% of Nephrocare Health Services Ltd (NEPHROPLUS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 8.78% and domestic institutional investors (DII) hold 9.05%. Market capitalisation was ₹6,530 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2025.
Largest disclosed public shareholders in Jun 2026: INVESTCORP INDIA INVESTMENTS HOLDING LIMITED 6.29%, POLAR CAPITAL FUNDS PLC - HEALTHCARE OPPORTUNITIES 5.76%, INTERNATIONAL FINANCE CORPORATION 3.08%, THE PRUDENTIAL ASSURANCE COMPANY LIMITED 1.87%, 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 9 1.3%, SBI HEALTHCARE OPPORTUNITIES FUND 1.19%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.85% | - | 8.78% | 9.05% | 36.15% |
| Mar 2026 | 63.85% | - | 9.94% | 8.65% | 36.15% |
| Dec 2025 | 63.85% | - | 9.3% | 8.1% | 36.15% |